| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$157.3M | ROE | −30.88% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody combining an EGFR-directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company is based in Boston, Massachusetts.
| Market Cap | $1.77B | Trading Days | 458 |
| 52W High | 30.99 |
| 52W Low | 9.57 |
| % Off High | −13.26% |
| YTD | 59.71% | 1Y | 127.60% |
| Since incept. (ann.) | 7.67% |
| Ann. Volatility (1Y) | 61.14% | Ann. Volatility (3Y) | 76.08% |
| Sharpe (1Y) | 1.71 | Sharpe (3Y) | 0.50 |
| Max Drawdown (1Y) | −26.43% | Max Drawdown (3Y) | −67.82% |
| Beta (3Y, vs SPY) | −0.73 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | $1.74B | — |
| DMRA | Damora Therapeutics, Inc. | $1.81B | — |
| STOK | Stoke Therapeutics, Inc. | $1.83B | — |
| TYRA | Tyra Biosciences, Inc. | $1.84B | — |
| BHC | Bausch Health Companies Inc. | $1.69B | 10.8 |
| OCUL | OCULAR THERAPEUTIX, INC | $1.85B | — |
| GENB | Generate Biomedicines, Inc. | $1.68B | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.88B | — |
| ZYME | Zymeworks Inc. | $1.65B | — |
| SLN | Silence Therapeutics plc | $1.64B | — |
| SRPT | Sarepta Therapeutics, Inc. |
| $1.63B |
| — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.92B | 7.2 |
